Network Insights Methodology Whitepaper Get Access

Novartis

ORG Health Care / Pharmaceuticals Momentum 10.1ML Momentum Score (0-100). Weighted composite of 9 features: mention velocity, article breadth, relationship density, deal context, recency, market cap, enrichment completeness, mention concentration, entity type. NORMALPSI regime classification. QUIET (<0.3): baseline activity. NORMAL (0.3-0.5): typical deal flow. ELEVATED (0.5-0.7): above-average signals. HIGH (0.7-0.85): significant activity. EXTREME (>0.85): exceptional signal concentration. Primary: Spectral Shift

$95B market cap (Basel) Novartis closed $1.1B upfront acquisition of UK biotech Myricx Bio for next-gen ADC platform access. Announced New Jersey job cuts while maintaining acquisition-driven pipeline expansion strategy.

Novartis acquiring Myricx Bio for $1.1B upfront to access next-generation antibody-drug conjugate (ADC) platform technology. Part of ongoing pharma M&A momentum extending into 2026.
0.29
PSI ScorePlocamium Signal Index - composite z-score from 5 orthogonal signals: news frequency, targeted sentiment, graph centrality, regulatory filings, and clinical trial activity.
10.1
MomentumML Momentum Score (0-100). Weighted composite of 9 features including mention velocity, article breadth, deal context, and relationship density. Retrained weekly.
1%
ConfidenceSignal confidence - percentage of PSI sub-signals with sufficient data (30+ observations). Higher confidence means the PSI score is based on more complete data.
26
ConnectionsDegree centrality - number of unique entities this entity co-occurs with in news signals and articles. Higher = more connected in the intelligence network.
Novartis is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Connected Entities
Merck China European Union PlocamiumAI United States Anthropic AstraZeneca CEO North Carolina Eli Lilly Texas United Kingdom DOD Senator Germany
Watch This Entity
PSI Intelligence
30-Day Trend
2026-06-14 2026-07-14 27 0 Degree Mentions
Signal Decomposition
Attention Cascade
3.333
Narrative Drift
0.000
Spectral Shift
666.425
Sentiment-Momentum Divergence
0.000
Source Concentration
0.803
Signal
Novartis is graph community structure is reorganizing around this entity — relationship patterns are changing (primary driver: Spectral Shift).
Driver
Ranked #6 of 75 in Health Care — above 93% of sector peers. PSI down 0.23 from yesterday (0.52 -> 0.29).
Action
Baseline conditions. Continue standard monitoring cadence.
Peer Comparison
6 of 75
Sector Rank
+1.17
Peer Z-Score
93%
Sector Percentile
Network Analysis
26 Degree Centrality
Ego Network (top connections)
Merck (weight 118.0)China (weight 9.0)European Union (weight 7.0)PlocamiumAI (weight 7.0)United States (weight 7.0)Anthropic (weight 5.0)AstraZeneca (weight 4.0)CEO (weight 4.0) MerckChinaEuropean UnionPlocamiumAIUnited StatesAnthropicAstraZenecaCEO Novartis (degree 26) Novartis
Centrality History
2026-06-14 2026-07-14 27 0 Degree Mentions
EntityWeight StatusFirst Seen
Merck 118 NEW
China 9 NEW
European Union 7 NEW
PlocamiumAI 7 NEW
United States 7 NEW
Anthropic 5 NEW
AstraZeneca 4 NEW
CEO 4 NEW
North Carolina 4 NEW
Eli Lilly 3 NEW
Texas 3 NEW
United Kingdom 3 NEW
DOD 3 NEW
Senator 2 NEW
Germany 2 NEW
Boeing 2 NEW
Intel 2 NEW
SEC 2 NEW
TSMC 2 NEW
New Jersey 2 NEW
FDA 2 NEW
Republicans 2 NEW
Airbus 2 NEW
Asia 2 NEW
BP 2 NEW
University of California 1 NEW
Article Coverage (0)
DateLaneTitle
No Plocamium-authored coverage yet. This entity surfaces in upstream signals (news, filings, trials) but has not yet been a primary subject of a published article. Watch this entity to be alerted when one is published.

Request Access

Full PSI intelligence, network analysis, EDGAR filings, and predicted links require an access token.

Data as of 2026-07-14 ← Intelligence Network